Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roche group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roche Group Today - Breaking & Trending Today

Five-year data from Genentech SMA study released

SMA patients in the long-term extension Evrysdi study maintained or improved key developmental skills over the five-year period, data shows. ....

United Kingdom , Giovanni Baranello , Levi Garraway , Research Clinical Care Meeting , Head Of Global Product Development , Roche Group , Institute Of Child Health Hospital , Ormond Street Institute , Child Health , Great Ormond Street Hospital , Chief Medical Officer , Global Product , Clinical Care ,

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic. ....

United States , Asia Pacific , Andrew Carlsen , Fosun Pharma , David Freundel , Judith Klimovsky , Globenewswire Inc , American Cancer Society , American Society Of Clinical Oncology , Exchange Commission , Roche Group , Clinical Oncology , Annual Meeting , Executive Vice President , Chief Development Officer , Chief Medical Officer , Media Release , Annual Report , Y Shaped Genmab , New Technologies , Private Securities Litigation Reform Act , Non Small Cell ,

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with. ....

United States , Judith Klimovsky , Fosun Pharma , David Freundel , Andrew Carlsen , Asia Pacific , Exchange Commission , American Society Of Clinical Oncology , American Cancer Society , Roche Group , Clinical Oncology , Annual Meeting , Executive Vice President , Chief Development Officer , Chief Medical Officer , Non Small Cell Lung Cancer , North America , Media Release , Annual Report , Y Shaped Genmab , New Technologies , Private Securities Litigation Reform Act , American Cancer , Non Small Cell Lung , Lung Cancer , Non Small Cell ,

Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC)

English

. ....

United States , Andrew Carlsen , Acasunlimab Duobody , Asia Pacific , Fosun Pharma , David Freundel , Roche Group , Global Communications Corporate Affairs , Exchange Commission , American Society Of Clinical Oncology , American Cancer Society , Clinical Oncology , Annual Meeting , Non Small Cell Lung Cancer , North America , Media Release , Annual Report , Y Shaped Genmab , New Technologies , Private Securities Litigation Reform Act , Senior Director , Global Communications , Vice President , American Cancer , Non Small Cell Lung , Accessed May ,

BioNTech SE: Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small ....

United States , David Freundel , Fosun Pharma , Andrew Carlsen , Judith Klimovsky , American Society Of Clinical Oncology , Exchange Commission , Roche Group , American Cancer Society , Clinical Oncology , Annual Meeting , Executive Vice President , Chief Development Officer , Chief Medical Officer , Non Small Cell Lung Cancer , Media Release , Annual Report , Y Shaped Genmab , New Technologies , Private Securities Litigation Reform Act , American Cancer , Non Small Cell Lung , Lung Cancer , Small Cell , Ihr Portfolio ,